Cargando…

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib

Although an array of new therapeutics has emerged for the treatment of colorectal cancer, their use is significantly impacted by variability in patient response. Better pre-clinical models could substantially improve efficacy as it may allow stratification of patients into the correct treatment regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Novo, Sonia M., Wedge, Stephen R., Stark, Lesley A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607258/
https://www.ncbi.nlm.nih.gov/pubmed/28931905
http://dx.doi.org/10.1038/s41598-017-12222-9